A patent application covering tenofovir, a major AIDS drug, has started a major patent fight in India.
If the drug is granted a patent, the manufacture of cheaper versions of tenofovir in India will become illegal, making the drug too expensive for many patients in developing nations, The International Herald Tribune reported Thursday.
The suit challenges Indian patent laws designed to control that country's large pharmaceutical industry, which has long specialized in making cheaper copies of Western manufactured medicines, the newspaper said.
The Indian patent office says it has received about 9,000 patent applications, most from international pharmaceutical companies.
But patient advocates warn the developing world's access to a wide range of vital generic drugs made in India might become jeopardized.
The Delhi Network of Positive People and the Indian Network for People Living with HIV/AIDS filed a formal protest Tuesday to a patent application from U.S.-based Gilead Sciences for the drug tenofovir.
The patient rights group argues tenofovir is not a new drug, just a modified version of an earlier drug, and therefore is not eligible for a new patent under India's laws.
Copyright 2006 by United Press International
Related stories:
Government's reliance on free market economics makes essential drug prices too high for the poor
Research in Malaysia, published in the latest
PLoS Medicine, has established that drugs considered essential for adequate health care are often priced beyond the reach of the poorer members of society. It would cost, for example, three days wages for a low-paid government worker to buy a month’s supply of a commonly prescribed stomach ulcer pill.
Nano World: National ranking in nanotech
The United States, Japan, Germany and South Korea dominate nanotechnology today, but in 2012 Taiwan should also leap into a leading role, with China making dramatic gains and France sliding into the minor leagues, experts told UPI's Nano World.
Biodegradable polymers show promise for improving treatment of acute inflammatory diseases
A family of biodegradable polymers called polyketals and their derivatives may improve treatment for such inflammatory illnesses as acute lung injury, acute liver failure and inflammatory bowel disease by delivering drugs, proteins and snips of ribonucleic acid to disease locations in the body.
Grow your mobile in a pot? Maybe someday, say Nokia researchers
With a mobile phone you can make calls on the go, shoot photos and pinpoint your position on a map. And who knows, maybe one day you'll be able to grow your phone in a pot, if the futuristic ideas of technology researchers come true.
New laser spectrometer opens the way for more effective carbon trading, drug development and carbon dating
Carbon offsets increasingly are becoming a major component in the arsenal for reducing global warming. Even Bon Jovi, the Rolling Stones and the Dave Matthews Band are doing it: acquiring carbon offsets to reduce the carbon footprint of their tours. As more organizations and businesses start trading in carbon offsets, the need for accurate measurements of carbon emissions also is becoming critically important for fair and exact exchanges.
New UGA invention effectively kills foodborne pathogens in minutes
University of Georgia researchers have developed an effective technology for reducing contamination of dangerous bacteria on food. The new antimicrobial wash rapidly kills Salmonella and E. coli O157:H7 on foods ranging from fragile lettuce to tomatoes, fruits, poultry products and meats. It is made from inexpensive and readily available ingredients that are recognized as safe by the U.S. Food and Drug Administration.
Duke chemist has new way to tell right from left
A Duke University chemist has apparently solved a long-standing frustration in creating certain synthetic molecules that make up drugs, which could lead to better drugs with fewer side effects.
Doctors can unmask deceptive high-risk breast tumors using genetic profile
A unique genetic signature can alert physicians to high-risk breast tumors that are masquerading as low-risk tumors, according to research at Washington University School of Medicine in St. Louis and collaborating institutions. Although these tumors are apparently estrogen-receptor positive — meaning they should depend on estrogen to grow — they don't respond well to anti-estrogen therapy.